This is an aggregated industry headline. Read the full story at FierceBiotech →
ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, detailed results from ivonescimab's chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes.
By FierceBiotech
· Jun 1, 2026
· via FierceBiotech
Image: FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become…
The WeekFierceBiotech ↗
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to San…
The WeekSTAT News ↗
Blumenthal, Hawley press UnitedHealth, Humana, CVS for documents related to using AI to deny or delay care.…